Archive ScienceWatch

 ScienceWatch

SPECIAL TOPICS

Rheumatoid Arthritis

Published: November 2008
 

The baseline time span for this database is (publication years) 1998-2008 from the third bimonthly update (a 10-year + 6-month period). The resulting database contained 33,844 (10 years) and 10,173 (2 years) papers; 82,701 authors; 120 nations; 2,515 journals; and 15,590 institutions. See additional paper information below in the overview & methodology sections.

Top 20 Papers

  10-year period
  2-year period

Top 20 Overall

  Authors
  Institutions
  Journals
  Nations

Research Front Maps

  " EARLY RHEUMATOID ARTHRITIS "
  " RHEUMATOID ARTHRITIS FOLLOWING RITUXIMAB TREATMENT "

Time Series

  1- & 5-year periods

Field Distribution

Interviews

  Interviews, first-person essays, and profiles about people in a wide variety of fields which pertain to this special topic of Rheumatoid Arthritis.
   

OVERVIEW

Rheumatoid arthritis is a chronic autoimmune disease causing inflammation in the lining of the joints and leading to long-term joint damage. According to the Arthritis Foundation and the NIH, 1.3 million Americans have rheumatoid arthritis, while in the UK, more than 350,000 people are affected. This month, Special Topics revisits an analysis we did two years ago by looking at the research trends in rheumatoid arthritis over the past decade and over the past two years.

Our analysis was based on a topic (title, abstract, and keywords) search for "rheumatoid arth*." To generate a more on-point list of the top 20 papers over the past decade and over the past two years, we further restricted these papers to the contain the keyword solely in the title.

Drug treatment trials dominate the 10-year list. Treatments investigated include rofecoxib, celecoxib, inflimixab alone or with methotrexate, entanercept alone or with methotrexate, anti-TNF antibodies, rituximab, adalimumab, leflunomide, sulphasalazine, and interleukin-1 receptor antagonists. The long-term gastrointestinal toxicity of rofecoxib and celecoxib are examined, as are the role of cytokine pathways in the mechanisms of joint inflammation and the diagnostic value of rheumatoid arthritis autoantibodies. Compared with our 2006 analysis, etanercept appears to be taking on a larger therapeutic role; in addition, studies into the mechanisms of disease are increasing.

Drug therapy also dominates the two-year list. Named trials include the PREMIER, TEMPO, and ASPIRE studies, as well as the British Society for Rheumatology Biologics Register. Drug treatments include anti-TNF antibodies, adalimumab, rituximab, abatacept, B-cell targeting, tocilizumab, etanercept, and glucocorticoids. Like the 10-year list, there are more papers speculating on the etiology of rheumatoid arthritis compared with the 2006 analysis, as well as more papers examining the diagnostic value of specific autoantibodies. Other concerns, such as the reconstitution of peripheral blood B cells after certain types of therapy and predictors of joint damage, are also addressed.

Methodology: The baseline time span for this database is (publication years) 1998-2008 from the third bimonthly update (a 10-year + 6-month period). The resulting database contained 33,844 (10 years) and 10,173 (2 years) papers; 82,701 authors; 120 nations; 2,515 journals; and 15,590 institutions.

Papers: To construct the top 20 papers lists for the past decade and the past two years, the papers were further narrowed down by the title keywords "rheumatoid arthritis." This adjustment resulted in the top 20 papers being selected from a pool of 8,898 (10 years) and 2,504 (2 years) papers.

Rankings: Once the database was in place, it was used to generate list of authors, journals, institutions, and nations. Rankings for author, journal, institution, and country are listed in three ways: according to total cites, total papers, and total cites/paper. The paper thresholds and corresponding percentages used to determine scientist, institution, country, and journal rankings according to total cites/paper, and total papers respectively are as follows:

Entity Authors Institutions Nations Journals
Thresholds 17 93 16 21
Percentage: 1% 1% 50% 10%


Analyses : Special Topics : Rheumatoid Arthritis
Special Topics
Complete Interview & Topic Menu - a list of all Special Topics with corresponding interviews, essays, or profiles.

More Analyses

Research News